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maintained its phosphorylation. Activation of ERK1/2 was 
only observed in response to IGF1. Loss of p-Akt/PKB (but 
not of p-ERK1/2) was associated with increased apopto-
sis, and protection from apoptosis was lost when activation 
of Akt/PKB was inhibited. These findings in Saos-2/B10 
cells were also replicated in the A549 cell line, originally 
derived from a human lung carcinoma. Therefore, IGF1 
and insulin more likely (at lower concentrations) enhance 
tumour cell survival than proliferation, via activation and 
maintenance of phosphatidylinositol 3-kinase activity and 
p-Akt/PKB.
Keywords Osteosarcoma cells · IGF1 · Insulin · 
Apoptosis · PI3K · Obesity
Introduction
Sufficient fuel and nutrient supply and growth hormone 
(GH) action are important for normal growth; in vivo, insu-
lin and insulin-like growth factor (IGF) 1 are intrinsically 
linked to anabolic, growth-friendly conditions. Obesity 
and acromegaly are deleterious conditions, associated with 
high insulin and IGF1 levels, and decreased life expec-
tancy. Obesity is characterized by increased fat mass, insu-
lin resistance, hyperinsulinemia, and an increased risk not 
only for type 2 diabetes but also for cancer; acromegaly is 
also characterized by insulin resistance but with decreased 
fat mass, and an excess of GH, insulin, and IGF1. Although 
the presence of anabolic hormones is usually perceived to 
be favourable, it has been realized that decreased action of 
GH, insulin, and IGF1 can increase life span and reduce 
tumour cell growth [1–3].
In vitro, insulin and IGF1 promote growth. Insulin 
was found to favour growth of breast cancer cells [4], and 
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insulin increases proliferation of the MCF-7 breast cancer 
cell line [5–9], and IGF1 is a potent mitogen for osteo-
sarcoma cells [8, 10–18]. These properties of insulin and 
IGF1 could underlie increased growth of breast cancer in 
obesity and of osteosarcoma in puberty. Insulin and IGF1 
share mitogenic pathways, including the mitogen-activated 
protein kinase (MAPK), extracellular signal-regulated 
kinase (ERK) and the phosphatidylinositol 3-kinase (PI3K) 
pathways [8, 11]. Receptors for IGF1 (IGF1R) and insulin 
(IR) and their downstream signal transduction pathways 
thus became therapeutic targets [19].
Dietary restriction decreases circulating levels of insu-
lin and IGF1, is antitumorigenic and increases life-span. 
The PI3K pathway may mediate the sensitivity of selected 
tumours to dietary restriction as tumours sensitive to die-
tary restriction were growth-responsive to insulin and 
IGF1 whereas tumours with constitutively active PI3K 
signalling were not. Decreased PI3K signalling in human 
tumour xenografts correlated better with dietary restric-
tion-induced apoptosis than with decreased proliferation; 
enhanced apoptosis was shown to contribute to net tumour 
cell growth suppression [20].
We analysed in more detail antiapoptotic effects of insu-
lin and IGF1 in two tumour cell lines, A549 non-small-cell 
lung cancer (NSCLC) and Saos-2/B10 osteoblastic osteo-
sarcoma cells, with a special focus on the latter since they 
have been found to be critically dependent on insulin-like 
signals for proliferation and especially survival in  vitro. 
Saos-2/B10 cells have been used to assess cancer-related 
safety of insulin analogues (IR binding agonists) with a 
focus on mitogenic potency, receptor activation and bind-
ing studies [13]. Increased affinity for the IGF1R was found 
to be strongly correlated with increased mitogenic potency 
as also confirmed by later studies [21]. Glargine, e.g., the 
first modified insulin to delay absorption and to prolong 
duration of action, has a 6–8-fold increased affinity for 
IGF1R and mitogenic potency compared with insulin [13, 
21]. Nevertheless, glargine is considered as safe, because 
it is converted to metabolites M1 and M2 with decreased 
activities at both IGF1R and IR but an apparently more 
favourable ratio of metabolic–mitogenic potency than the 
native compound [22–25].
Overall, concentrations of insulin and insulin analogues 
in vivo (in healthy individuals and in patients with diabe-
tes) are normally low compared to the levels required to 
elicit a mitogenic response. As indicated above, tumour 
growth could depend on both, regulation of apoptosis and 
mitogenesis. We therefore analysed in more detail antia-
poptotic effects of insulin and IGF1 in the Saos-2/B10 
cell line which was found to be critically dependent on 
insulin-like signals for proliferation and especially survival 
in  vitro. We compared the effects of insulin and IGF1 to 
those of glargine and those of FCS, tested the interference 
of IGF-binding protein (IGFBP) 3 (inhibitor of IGF1) and 
of wortmannin (WT, inhibitor of PI3K), and analysed the 
signal transduction pathways involved.
Materials and methods
Cell culture
Saos-2 is an osteosarcoma cell line which was origi-
nally derived from a 14-year-old female (ATCC HTB 85, 
American Type Culture Collection. Rockville, MD); it was 
characterized in more detail and subcloned to yield the 
osteoblastic osteosarcoma line Saos-2/B10 [26, 27]. These 
cells are p53-negative [14, 28] and produce no IGF1 [10, 
29]. They were passaged in Falcon tissue culture flasks in 
DMEM/Ham’s F-12 medium (Gibco 31885/21765) con-
taining 50  µg/ml gentamicin, 2  mmol/l l-glutamine, and 
10% (v/v) FCS at 37   °C in an atmosphere of 5%  CO2. 
Cells (passage 16–33) were cultured in DMEM [50  µg/
ml gentamicin, 2  mmol/l l-glutamine and 5% (v/v) FCS] 
for 3 days prior to the start of experiments. A549 is a lung 
(alveolar cell) adenocarcinoma cell line which was origi-
nally derived from a 58-year-old Caucasian male (ATCC, 
Rockville, MD; ECACC no. 86012804) [10, 30]. A549 
cells belong to the family of NSCLC cells and to the adeno-
carcinoma histological subtype with epithelial origin. They 
contain wild-type p53 [31]. These cells were cultured (pas-
sage 7–24) in Falcon tissue culture flasks in RPMI (Gibco 
31870) containing 2  mM l-glutamine, 50  µg/ml gen-
tamicin, and 10% (v/v) FCS at 37 °C in an atmosphere of 
5%  CO2.
Under serum-free conditions, Ham’s F-12 medium was 
used with 1 g/l free fatty acid-free BSA (from Sigma, St. 
Louis, MO, USA). IGF1 was from Ciba-Geigy, Basel, 
Switzerland, insulin from Novo Nordisk, Gentofte, Den-
mark, and the insulin analogue glargine from Sanofi-
Aventis, Frankfurt, Germany. rhIGFBP3 and pharmacolog-
ical inhibitors of PI3K (WT: Sigma, Buchs, Switzerland) 
or MEK (UO126 or PD98059: Sigma, Buchs, Switzerland) 
were added as indicated.
Assessment of proliferation
Cells (21 × 103 per  cm2) were plated in 5% FCS-containing 
medium. After 3 days of growth, confluent cultures were 
rinsed with serum-free medium, and incubated for 18  h 
in serum-free Ham’s F-12 medium containing 1  g/l BSA 
and growth factors as indicated. DNA synthesis was meas-
ured by methyl-[3H]-thymidine (Amersham, 89  Ci/mmol; 
0.5 µCi per dish) incorporation during a 3-h pulse follow-
ing exposure to test media for 18–21 h [32].
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Assessment of apoptosis
Cells were plated as described for proliferation, washed, 
and incubated for 4  h in serum-free Ham’s F-12 medium 
containing 1 g/l BSA; growth factors and test compounds 
were added as shown in Fig. 1a.
Cells were washed with ice-cold PBS, and lysed into 
400  µl of kit lysis buffer and centrifuged for 10  min at 
200×g at room temperature. A 20 µl volume was used for 
analysis (Cell Death Detection  ELISAPLUS from Boehringer 
Mannheim) following the manufacturer’s instructions [29, 
32]. This method measures cytosolic oligonucleosome-
bound DNA and allows quantitative determination of 
histone-associated DNA fragments. It is based on a sand-
wich-enzyme immunoassay which detects enrichment of 
mono- and oligonucleosomes in the cytoplasmic fraction of 
cell lysates by monoclonal antibodies directed against DNA 
and histones [29].
Immunoblotting
Cells were lysed in 50 mmol/l HEPES pH 7.5, 140 mmol/l 
NaCl, 1 mmol/l PMSF, 0.5% Triton X-100, 10 mmol/l NaF, 
1 mmol/l  Na2H2P2O7, 1 mmol/l  Na2O4V, 3 µg/ml aprotinin, 
3  µg/ml leupeptin. Equal amounts of protein (concentra-
tion determined using the bicinchoninic acid protein assay 
kit from Pierce) were separated by SDS-PAGE (NuPAGE, 
Invitrogen) and transferred onto nitrocellulose membranes. 
2% Non-fat milk in TBST [10  mmol/l Tris–HCl, pH 7.4, 
150  mmol/l NaCl, 0.05% (v/v) Tween 20] was used to 
block nonspecific binding of antibodies to membranes. 
Incubation with primary and secondary antibodies was 
either at room temperature for 1  h or overnight at 4 °C. 
Immuno-reactive proteins were visualized by the Lumi-
Light Western blotting substrate (Roche) using a LAS-3000 
imaging system (Fuji). Signal intensities were quantified 
using the AIDA software package (Raytest). Equal loading 
Fig. 1  Flow diagram of 
experimental protocols. Cells 
were grown in FCS-containing 
media for 3 days and exposed to 
serum-free, albumin-containing 
test media as shown. Apopto-
sis was assessed after 4 h (a, 
“common stop”) by an ELISA 
detecting cytosolic oligonucle-
osomes. Insulin/IGF1 signal-
ling was analysed by Western 
blotting using antibodies against 
the unphosphorylated and phos-
phorylated forms of IR-IGF1R-
IRS1 (not shown), Akt/PKB 
and ERK1/2, and actin, with 
“common stop” (a) and with 
“common start” (b) protocols as 
indicated
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and transfer were confirmed with an antibody against actin 
(MAB1501: EMD Millipore, Temecula, USA). Insulin/
IGF-dependent signalling was assessed with antibodies 
against the phosphorylated forms of Akt/protein kinase B 
(PKB; Ser473: Cell Signaling, Danvers, USA) and ERK1/2 
(Thr202/Tyr204: Cell Signaling, Danvers, USA). Activa-
tion of IR and IGF1R was monitored using an antibody 
against p-Tyr (clone 4G10, EMD Millipore, Temecula, 
USA). Expression levels of Akt/PKB, ERK1/2, IR, IGF1R, 
IRS1, actin, and LC3A/B were assessed with specific anti-
bodies [Akt/PKB: BD Transduction Laboratories, San Jose, 
USA; ERK1/2: Cell Signaling, Danvers, USA; insulin Rβ, 
IGF1Rβ, and IRS1: Santa Cruz, Dallas, USA; actin: clone 
C4, MAB1501, Millipore/Merck, Darmstadt, Germany; 
LC3A/B: (DRU4C) Rabbit mAb, Cell Signaling, Danvers, 
USA].
Statistical analysis and presentation of data
At least three Western blots with duplicates or at least five 
ELISA or 3H-incorporation studies (carried out in tripli-
cate), respectively, were combined. Data are expressed 
as means ± SEM. In the case of Western blots, results 
of quantifications are plotted on a log scale normalized 
to protein amount and relative to control; values were 
highly consistent between experiments regardless of nor-
malization to protein (as loaded), total (phosphorylated 
plus nonphosphorylated proteins) Akt/PKB and ERK/
MAPK or actin. Statistical significance was assessed by 
the unpaired two-sided Student’s t-test or by ANOVA. 
p < 0.05 was considered statistically significant.
Results
Insulin and IGF1 increase proliferation and potently 
inhibit apoptosis in Saos-2/B10 cells
Insulin and IGF1 stimulated  [3H]-thymidine incorpora-
tion into DNA in a dose-dependent manner, with increas-
ing concentrations up to the same maximum (Fig.  2a). 
IGF1 was more potent and half-maximal stimulation was 
reached at lower concentrations of IGF1 (0.4  nmol/l) 
compared to insulin (20 nmol/l).
Serum withdrawal results in apoptosis of Saos-2/
B10 cells within hours. Inclusion of IGF1 or IGF2 in 
test media protects Saos-2/B10 cells against apoptosis 
[29, 32]. We wanted to test if inclusion of insulin had a 
similar effect. Figure 2b shows dose–response curves for 
insulin and IGF1. Lower doses of IGF1 or insulin were 
sufficient to inhibit apoptosis compared to DNA syn-
thesis. IGF1 was more potent compared to insulin with 
half-maximal values at 0.04 versus 1.0 nmol/l for insulin. 
IGF1 (at 1 nmol/l) and insulin (at 100 nmol/l) decreased 
apoptosis to a similar extent.
Fig. 2  Insulin and IGF1 
regulate proliferation and 
apoptosis of Saos-2/B10 cells. 
a Stimulation of  [3H]-thymidine 
incorporation into DNA by 
IGF1 and insulin. Cells were 
grown in 5% FCS-containing 
media for 3 days and exposed to 
serum-free, albumin-containing 
test media, containing IGF1 
or insulin. DNA synthesis was 
measured by a  [3H]-thymidine 
pulse 18–21 h following 
exposure to test media (n = 6). b 
Inhibition of apoptosis by IGF1 
and insulin. Cells were exposed 
to test media containing IGF1 
or insulin as shown in Fig. 1a. 
Apoptosis was assessed after 
4 h. Results are expressed rela-
tive to control (n = 5)
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Insulin and IGF1 activate Akt/PKB and ERK1/2 
in Saos-2/B10 cells: time and dose dependence
Activation of insulin/IGF1-dependent signalling in 
Saos-2/B10 cells was studied with phospho-specific 
antibodies against Akt/PKB (p-Ser473) and ERK1/2 
(p-Thr202/Tyr204). Time dependence and dose depend-
ence were analysed (Figs.  3, 4, respectively). IGF1 and 
insulin both activated Akt/PKB strongly within min-
utes; sustained activation of Akt/PKB was observed in 
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Fig. 3  Time-dependent activation of Akt/PKB and ERK1/2 by IGF1 
and insulin in Saos-2/B10 cells. Representative Western blots are 
shown on top; quantification of signals from at least four independ-
ent experiments below. Abundance of p-Akt/PKB and p-ERK1/2 is 
shown relative to control (4 h). Cells were exposed to vehicle (empty 
symbols), to 1 nmol/l IGF1 (filled squares) or to 100 nmol/l insulin 
(filled triangles) as outlined in Fig. 1b, and incubations were stopped 
after 10, 30, 120, and 240 min
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response to both IGF1 and insulin while ERK1/2 activa-
tion was rather transient, and only observed in response 
to IGF1 (Fig. 3b). We consistently observed a decrease in 
phosphorylation of ERK1/2 after longer exposures (4 h), 
and insulin was more effective than IGF1 in this regard. 
Quantification of at least seven independent experiments 
is shown with numerical values (plotted on a log scale) in 
the lower panels.
Dose-dependent phosphorylation/activation of Akt/
PKB and ERK1/2 after 30  min of exposure to IGF1 or 
insulin is shown in Fig. 4. IGF1 was more potent in phos-
phorylating Akt/PKB than insulin. The dose–response 
curves are broad, and our data cannot reveal whether 
maximal stimulation of p-Akt/PKB was achieved at 
10  nmol/l IGF1; maximal activation was not reached at 
100  nmol/l insulin, the highest concentration that was 
tested; thus, concentrations required for half-maximal 
stimulation of Akt/PKB  (EC50) cannot be given. ERK1/2 
phosphorylation dependent on stimulation with IGF1 was 
much less pronounced compared to Akt/PKB, and insulin 
even at high concentrations barely increased p-ERK1/2.
Time-dependent inhibition of apoptosis in Saos-2/B10 
cells by IGF1 and insulin
To test how long after serum withdrawal cells could be 
rescued from apoptosis, IGF1 or insulin were added to 
supernatants at different time points after serum with-
drawal. Maximal inhibition of apoptosis was observed 
when IGF1 or insulin (or glargine, not shown) was added 
at least 2 h prior to the end of the 4-h incubation time 
(Fig.  5), i.e., not later than 2 h after serum withdrawal. 
At this time point, residual Akt/PKB phosphorylation 
in serum- and hormone-free control conditions was low 
(Fig.  3). IGF1 or insulin promptly increased Akt/PKB 
phosphorylation at all tested time points, i.e., also with 
the protocol of Fig. 1a, “common stop”, as well as with 
the protocol of Fig.  1b, “common start”. ERK1/2 was 
activated after short-term exposure to IGF1; strikingly, 
after 4-h exposure, p-ERK was consistently decreased in 
cells exposed to IGF1 or (more clearly) insulin, relative 
to control (Figs. 3, 5).
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Fig. 4  Dose-dependent activation of Akt/PKB and ERK1/2 by IGF1 
and insulin in Saos-2/B10 cells. Cells were exposed to IGF1 (a) and 
insulin (b) for 30 min as described in Fig. 1b (common start). Rep-
resentative Western blots are shown on top, below quantification of 
at least four independent experiments. Abundance of p-Akt/PKB and 
p-ERK1/2 is expressed relative to control
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IGFBP3 inhibits IGF1- but not insulin-dependent 
regulation of apoptosis in Saos-2/B10 cells
rhIGFBP3 can effectively block IGF1-induced prolifera-
tion and survival in cell culture experiments [17, 29, 32, 
33]. In order to test whether apoptosis was regulated by 
IGF1 and insulin also in the presence of IGFBP3, cells 
were serum-deprived for 4 h in the absence or presence 
of IGF1, insulin, or glargine. 10  nmol/l rhIGFBP3 was 
added to the cells 30, 60, 120, or 240  min prior to the 
end of incubation (Fig. 6). Apoptosis was not changed in 
Saos-2/B10 cells exposed to rhIGFBP3 alone. 10 nmol/l 
rhIGFBP3 did not inhibit the apoptosis-preventing effects 
of 100  nmol/l insulin [32] and of 1  nmol/l glargine but 
selectively inhibited the apoptosis-preventing effects of 
1  nmol/l IGF1; 10  nmol/l rhIGFBP3 was effective (in 
the presence of IGF1) if added at least 120  min prior 
to the end of the 4  h incubation time. Correspondingly, 
rhIGFBP3 blocked Akt/PKB phosphorylation dependent 
on incubation with 1 nmol/l IGF1 but not with 100 nmol/l 
insulin or 1 nmol/l glargine (not shown).
Wortmannin inhibits IGF1- and insulin-dependent 
regulation of apoptosis in Saos-2/B10 cells
To test if activation of Akt/PKB and/or ERK1/2 are 
required for insulin/IGF1-dependent regulation of apop-
tosis in Saos-2/B10 cells, we used WT and UO126/
PD98059 to inhibit their activation, respectively. We 
first confirmed by Western blotting that preincubating 
cells with these inhibitors for 10 min prior to exposure to 
1 nmol/l IGF1 or 100 nmol/l insulin for 30 min blocked 
activation of Akt/PKB and/or ERK1/2. 100 (but not 20) 
nmol/l WT reliably blocked Akt/PKB phosphorylation, 
and 50  µmol/l UO126 or 20  µmol/l PD98059 blocked 
ERK phosphorylation under these conditions (not 
shown). WT (Fig.  7) but not UO126 or PD98059 (both 
not shown) interfered with protection from apoptosis by 
both IGF1 and insulin. WT had to be present for 4 h for 
this effect; however, more than half-maximal protection 
from apoptosis was still found when WT was added only 
for the last 3 h. In addition, cells cultured for 4 h in the 
presence of WT showed reduced activation of Akt/PKB 
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Fig. 5  Time-dependent inhibition of apoptosis and activation of sig-
nalling by IGF1 and insulin in Saos-2/B10 cells. Cells were cultured 
in serum-free media for the last 4  h as shown in Fig.  1a (common 
stop). IGF1 (a, 1 nmol/l) or insulin (b, 100 nmol/l) was added to the 
media 30 min, 1 h, 2 h, or 4 h prior to stop. Apoptosis is shown at the 
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blots in lower panels
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by IGF1 and by insulin but marked phosphorylation of 
Akt/PKB was still observed when WT was added only 
for the last 3  h (not shown). WT alone, when present 
throughout 4 h, increased apoptosis in the control condi-
tion (Fig. 7).
Comparing effects of IGF1 and insulin with those 
of glargine and FCS in Saos-2/B10 cells
As in the case of IGF1 (low doses) and insulin (high doses), 
exposure of Saos-2/B10 cells to glargine also resulted 
Fig. 6  Time-dependent 
interference of IGFBP3 with 
apoptosis inhibition by IGF1 
and glargine in Saos-2/B10 
cells. Cells were cultured in 
serum-free media for 4 h in the 
absence or presence of 1 nmol/l 
IGF1 (a, n = 5) or 1 nmol/l 
glargine (b, n = 3) as shown in 
Fig. 1a (common stop). IGFBP3 
(10 nmol/l) was added 30 min, 
1 h, 2 h, and 4 h prior to stop 
(n = 5)
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Fig. 7  Time-dependent inter-
ference of wortmannin with 
apoptosis inhibition by IGF1 
and insulin in Saos-2/B10 cells. 
Cells were cultured in serum-
free media containing 1 nmol/l 
IGF1 (a, n = 5) or 100 nmol/l 
insulin (b, n = 3), as shown in 
Fig. 1a (common stop). WT 
(100 nmol/l) was added 1, 2, 3, 
and 4 h prior to stop
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in activation of Akt/PKB and protection from apoptosis 
(Fig.  8). Significant effects on apoptosis (but not on pro-
liferation) were seen in response to 0.1  nmol/l glargine. 
Likewise, concerning activation of Akt/PKB and ERK1/2, 
it appeared that the potency of glargine was intermediate 
between that of IGF1 and insulin. FCS (5%) tended to be 
more effective in activating ERK1/2 and in stimulating 
DNA synthesis, but it tended to be less potent than IGF1 
and insulin in protecting Saos-2/B10 cells from apoptosis 
and increasing p-Akt/PKB.
Insulin and IGF1 regulate proliferation and apoptosis 
in A549 cells
In order to test if our findings in Saos-2/B10 can be repro-
duced in another human cell line, we repeated a subset of 
our experiments with A549 cells [10, 30].
First we analysed time- (Fig.  9) and dose-dependent 
(Fig. 10, top panel) regulation of Akt/PKB and ERK1/2 by 
insulin and IGF1 with phospho-specific antibodies against 
Akt/PKB (p-Ser473) and ERK1/2 (p-Thr202/Tyr204). 
IGF1 and insulin both activated Akt/PKB strongly within 
minutes in A549 cells as they did in Saos-2/B10 cells; sus-
tained activation of Akt/PKB was observed in response to 
both IGF1 and insulin. ERK1/2 activation was less pro-
nounced and transient.
Figure 10 summarizes dose-dependent activation of Akt/
PKB and ERK1/2 as well as regulation of proliferation and 
apoptosis in A549 cells. Insulin or IGFI both protected 
A549 cells from apoptosis and stimulated DNA synthesis. 
As in Saos-2/B10 cells, IGF1 (at lower doses) and insu-
lin (at higher doses) were more effective in increasing and 
maintaining Akt/PKB phosphorylation and protecting cells 
from apoptosis while regulation of ERK1/2 and stimulation 
of DNA synthesis was less sensitive.
We also tested the effects of IGFBP3 and of WT in A549 
cells (not shown). For both test compounds, results were as 
found for Saos-2/B10 cells. rhIGFBP3 blocked the effects 
of IGF1 but not those of insulin; per se, it slightly enhanced 
apoptosis which appears consistent with a role for endog-
enous IGF1 in the survival of A549 cells; autocrine IGF1 
may also be related to their lower IGF1R number and their 
lower sensitivity to insulin/IGF1 as compared with Saos-2/
B10 cells [10]. WT fully blocked IGF1- and insulin-stim-
ulated Akt/PKB phosphorylation, and it decreased basal/
residual p-Akt/PKB within 30  min of exposure. WT also 
interfered with protection from apoptosis by both 1 nmol/l 
IGF1 and 100 nmol/l insulin, and, when present throughout 
4 h, increased apoptosis in the control condition.
Discussion
Osteosarcoma is a malignant bone tumour with an inci-
dence peak coinciding with the adolescent growth spurt, 
a time when the hormonal milieu is characterized by high 
GH, IGF1 and insulin levels. Osteosarcoma growth may be 
particularly dependent on IGF1 [12, 16, 18]. The Saos-2/
Fig. 8  Effects of IGF1, insulin, 
glargine, and FCS compared 
in Saos-2/B10 cells. Cells 
were exposed to IGF1, insulin, 
glargine, or FCS as described 
for Figs. 2 and 4. Top panel 
Western blot showing p-Akt/
PKB, p-ERK1/2, bottom panel 
stimulation of DNA synthesis 
and inhibition of apoptosis, 
expressed relative to control 
(log scale), n = 7. c denotes 
control, ***p < 0.0001
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B10 subline model has been well characterized and used 
extensively to elucidate actions of IGF1, IGF2, IGFBPs, 
insulin, and analogues [10, 13, 17, 29, 32, 33].
IGF1 and insulin activated Akt/PKB in Saos-2/B10 
cells and concomitantly protected against apoptosis  (EC50 
for inhibition of apoptosis, 0.04 nmol/l for IGF1, 1 nmol/l 
for insulin). Saos-2/B10 cells were (approximately 10-fold) 
more sensitive to IGF1 in terms of inhibition of apoptosis 
than with regard to stimulation of DNA synthesis. In the 
case of insulin (and of glargine), this difference was even 
more pronounced, approximately 20-fold. Apoptosis was 
inhibited to a similar minimum by IGF1, insulin, or glar-
gine, but higher concentrations of insulin or glargine were 
required. Effects of IGF1 but not those of insulin and glar-
gine were blocked by IGFBP3. FCS-containing media 
(without addition of IGF1 or insulin) also activated Akt/
PKB and protected from apoptosis (Fig. 8). Media contain-
ing 5% FCS were more effective than IGF1 or insulin in 
activating ERK1/2/MAPK and in stimulating DNA synthe-
sis, but less potent than 1 nmol/l IGF1 or 100 nmol/l insulin 
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Fig. 9  Time-dependent activation of Akt/PKB and ERK1/2 by IGF1 
and insulin in A549 cells. Representative Western blots are shown on 
top; quantification of signals from two independent experiments (with 
duplicates) below. Abundance of p-Akt/PKB and p-ERK1/2 is shown 
relative to control (4 h). Cells were exposed to vehicle (empty sym-
bols), to 1 nmol/l IGF1 (filled squares) or to 100 nmol/l insulin (filled 
triangles) as outlined in Fig. 1b, and incubations were stopped after 
10, 30, 120, and 240 min (as in Fig. 3). M denotes markers
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in protecting Saos-2/B10 cells from apoptosis within 4 h, 
and 5% FCS was also less effective in stimulating p-Akt/
PKB within 30 min (Fig. 8). These findings together with 
the blocking effects of WT are in line with the notion that 
signalling through IGF1R/IR and Akt/PKB promotes sur-
vival of Saos-2/B10 cells upon serum withdrawal. Most 
previous studies assessed DNA synthesis in vitro and sug-
gested that insulin concentrations that stimulated DNA 
synthesis in  vitro were probably not reached in  vivo [13, 
34]. However, as we show here, this is not necessarily the 
case when considering antiapoptotic effects. Insulin (either 
endogenous or exogenous) could well reach concentra-
tions which may contribute to survival of selected malig-
nant tumour cells, especially in insulin-resistant patients. 
In view of the low concentrations required for apoptosis 
prevention, the potential of insulin and analogues in main-
taining certain malignant cells in a vital state may have 
been underestimated. It appears that characterization of IR 
binding agonists should include assays on prevention of 
apoptosis and not restrict the focus on mitogenic potency. 
It has been proposed that specificity of ligand–receptor 
interactions defines biological response. Usually, insulin 
promotes proliferation of tumour cells only at higher con-
centrations than IGF1, possibly since it predominantly acts 
via type 1 IGFRs. Glargine is more potent than insulin with 
regard to IGF1R phosphorylation [35–37] and with regard 
to stimulation of proliferation [7, 9, 13, 21, 35]. Glargine is 
also (around seven to eight times) more potent than insu-
lin with regard to inhibition of apoptosis. However, insulin 
and IGF1 have overlapping receptor binding characteristics 
and share intracellular signalling pathways, including IR 
substrates, PI3K- and ERK-dependent pathways [38]; spec-
ificity of insulin versus IGF action is far from being under-
stood [39].
An important finding of our study is that IGF1 and insu-
lin effectively increase and maintain Akt/PKB in its phos-
phorylated state and concomitantly protect the cells from 
undergoing apoptosis. Inhibition of apoptosis was sensitive 
to WT, a widely used inhibitor of the PI3K-Akt/PKB axis 
[40–42]. IGF1 and insulin induced a prompt, strong and 
sustained activation of Akt/PKB while ERK1/2 was acti-
vated only transiently, and only by IGF1 and not by insulin. 
Compounds preventing activation of ERK1/2 (UO126 and 
PD98059) failed to inhibit the apoptosis-preventing effects 
of IGF1 and insulin. Our observation that insulin effec-
tively prevented apoptosis yet barely activated ERK1/2 also 
suggests that prevention of apoptosis by insulin or IGF1 
does not depend on activation of ERK1/2. In this context, it 
appears less important at which receptor(s) signalling initi-
ates, as signals finally converge at the level of PI3K to pre-
vent apoptosis. Therefore, we propose that in  vitro safety 
tests with insulin analogues should include assays address-
ing apoptosis and activation/maintenance of PI3K-depend-
ent signalling, rather than activation of different IR/IGF1R 
types. Indeed, Akt/PKB is central to a well-studied sur-
vival pathway and a known protooncogene [43–46]. Akt/
PKB is frequently hyperactivated in osteosarcoma [19]. It 
promotes cell survival by phosphorylating and inactivating 
several pro-apoptotic targets, such as Bad and the forkhead 
transcription factors. Overall, Akt/PKB is one of the most 
Fig. 10  Dose-dependent 
effects of IGF1 and insulin on 
signalling, proliferation, and 
apoptosis in A549 cells. Cells 
were exposed to IGF1 or insulin 
as described for Figs. 2 and 4, 
and data are shown as in Fig. 8 
for Saos-2/B10 cells. Top panel 
Western blot showing p-Akt/
PKB, p-ERK1/2, bottom panel 
stimulation of DNA synthesis 
(n =  7 in triplicate) and inhibi-
tion of apoptosis (n  =  2 in 
triplicate), expressed relative to 
control (log scale). c denotes 
control, ***p  <  0.0001
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frequently activated kinases in human cancer, and ectopic 
expression of a dominant-negative kinase-dead variant 
inhibited the ability of IGF1 to prevent apoptosis in Saos-2 
cells [11]. Our findings with Saos-2/B10 cells concur with 
the report by Kalaany and Sabatini [20] who also came to 
the conclusion that continuous exposure to insulin-like sig-
nals possibly more often helps tumour cells to survive than 
directly favours tumour growth progression by increasing 
mitogenesis.
Insulin-regulated autophagy was reported recently to link 
diabetes and cancer [47]. Indeed, autophagy may induce or 
prevent cell death, dependent on the cells under study and 
the context, as also reported for osteosarcoma cells [48]. 
Microtubule-associated protein 1 light chain 3 (MAP-LC3) 
is converted from the LC3-I (16 kDa) to the active LC3-II 
(14 kDa) form indicating increased autophagy flux. In our 
cell culture conditions, LC3-II did not appear to increase 
after serum withdrawal, and decreased only to a minor 
extent by IGF1 and insulin after 2 and 4 h (supplemental 
Fig.  1). Within the short time frame of our experimental 
setting, we found no obvious correlation between phospho-
rylation of Akt/PKB and induction of autophagy, in con-
trast to the strong correlation between phosphorylation of 
Akt/PKB and inhibition of apoptosis. Our study does not 
allow to clarify or exclude a potential role of autophagy in 
the regulation of apoptosis.
We show experiments just for two cell lines, and results 
therefore should be confirmed in other models. In both cell 
lines, we observed the same close relationship between 
activation and maintenance of Akt/PKB and protection 
from apoptosis. However, there were quantitative differ-
ences regarding potencies of IR/IGF1R agonists which may 
be due to known variations in expression levels of IGF1 
and IGF1R [10]. It has to be kept in mind that Saos-2/B10 
cells are particularly sensitive to IR/IGF1R agonists; other 
tumour cell types could be less sensitive. Another limita-
tion of our study was the use of pharmacological inhibitors 
to downregulate the activation of Akt/PKB and ERK1/2. 
Such compounds could exert unspecific effects, especially 
with longer incubation times. However, we have focused 
our study on the regulation of apoptosis in the short term 
(up to 4 h) where fewer overall toxic effects are expected. 
Conclusive evidence for the requirement of Akt/PKB in 
insulin/IGF1-induced survival of Saos-2/B10 cells requires 
specific knock-down (e.g., by siRNAs). To test if their 
activation is not only required for insulin/IGF1 effects but 
also sufficient for regulation of survival ectopic activation 
of downstream components (as, e.g., in [49]) would be 
required.
In healthy humans, insulin is secreted in pulsatile bursts 
[50]. Not only loss of early phase insulin response to glu-
cose but also the disruption of high frequency pattern of 
insulin secretion during fasting is characteristic of beta 
cell failure in type 2 diabetes [51]. Indeed, insulin given 
as intravenous pulses has greater glucoregulatory activ-
ity than insulin by continuous infusion [52, 53]; this may 
account for increased insulin dose requirement of flat pro-
file long-acting insulin analogues [54]. Normal regulation 
of blood glucose in healthy subjects with pulsatile insulin 
secretion includes periods of low insulin concentrations. In 
contrast, standard basal insulin replacement modalities fail 
to mimic this physiological insulin secretion pattern. Our 
in  vitro study addressed insulin/IGF-dependent regulation 
of apoptosis and phosphorylation of Akt/PKB under condi-
tions of continuous or interrupted stimulation. Within the 
4 h following FCS withdrawal IGF1 and insulin effectively 
activated Akt/PKB and prevented apoptosis, also when 
added with a 2-h delay (Fig. 5). Moreover, p-Akt/PKB was 
decreased and protection from apoptosis was lost when 
IGF1 was blocked by later addition of IGFBP3 for at least 
2 h (Fig. 6).
Our results indicate that apoptosis is prevented in 
Saos-2/B10 and A549 cells by signalling through the PI3K-
Akt/PKB pathway which is activated and remains active 
upon continuous exposure to IGF1 or insulin. Furthermore, 
lower concentrations of IR/IGF1R agonists are required for 
preventing cell death than for stimulating cell proliferation.
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